For decades, diagnostic imaging manufacturers have anchored their growth strategies to clinical demand, capital cycles, and incremental modality innovation. However, a quieter (and potentially more disruptive) shift is now underway upstream in the life sciences.…

The NIH’s growing emphasis on New Approach Methodologies (NAMs) marks a significant change in how biomedical research, particularly drug development, is being conducted. Prompted by legislative changes, evolving regulatory guidance, and long-standing concerns about the…

This winter’s respiratory season looks different from what many expected. Flu has once again pulled ahead of COVID in infections and hospitalizations, and the two illnesses are starting to resemble each other in how severe…

The 3D cell culture market has been on a strong and sustained growth trajectory, driven primarily by the pharmaceutical and biotechnology industries. Now, a regulatory shift is poised to further amplify that momentum. The FDA…

Since the FDA and NIH signaled their pivot toward New Approach Methodologies (NAMs) early last year, the most meaningful developments have been in how quickly those signals have turned into practical pathways. FDA’s 2025 roadmap…